- Fast Delivery
- 3rd Party Tested
- USA Manufactured
EU and UK, Allow 3-5 Working Days For Delivery
Semax and Selank appear quite often together in research which can make them seem like two versions of the same compound.
Semax is commonly investigated in research examining neurotrophic signalling, gene expression and responses to neurological stress meaning it may influence the biological processes involved in how nerve cells adapt, communicate, repair and protect themselves during periods of stress or injury.
Selank is more often studied in relation to pathways involving GABA, stress responses and communication between the nervous and immune systems meaning it may influence how the brain regulates anxiety and stress while also affecting signalling between the nervous system and immune system.
GABA, or gamma aminobutyric acid, is the main inhibitory neurotransmitter in the central nervous system. An inhibitory neurotransmitter is a chemical messenger that reduces certain forms of activity between nerve cells.
Despite appearing in similar research discussions, Semax and Selank were developed from different parent molecules.
Semax is derived from a short fragment of adrenocorticotropic hormone, known as ACTH. Selank is an analogue of tuftsin, a naturally occurring peptide associated with immune regulation.
Semax and Selank are synthetic heptapeptides, meaning that they are short peptides made up of seven amino acids.
The amino acid sequence of Semax is Met Glu His Phe Pro Gly Pro. The sequence of Selank is Thr Lys Pro Arg Pro Gly Pro.
Both compounds end with the same Pro Gly Pro sequence. However, their first four amino acids are different. This is important because the biological properties of a peptide depend on its complete structure, not simply one section shared with another molecule.
The difference between their complete sequences means that findings involving Semax cannot automatically be applied to Selank, or the other way around. Each compound must be examined according to the molecule and research model used in the study.
Semax and Selank are often compared because they emerged from the same wider area of Russian peptide research.
Both have also been investigated in studies involving the central nervous system.
Their similar length, shared research history and appearance within neurological studies have encouraged researchers and online communities to discuss them together.
Simplified comparisons often associate Semax with cognition and Selank with calming responses.
These descriptions provide only a limited summary of the available research. The compounds have been investigated through different experimental models, biological pathways and study endpoints.
A clearer comparison therefore requires examining how each compound has been studied and what the available evidence can support.
Semax research has mainly examined neurotrophic signalling, gene expression and communication between different regions of the brain.
Most of the available evidence comes from laboratory and animal studies, although some human imaging research has also been conducted.
A recurring subject in Semax research is brain derived neurotrophic factor (BDNF), a protein involved in the development, maintenance and communication of nerve cells.
Nerve growth factor (NGF) has also been studied. This protein helps regulate the development and maintenance of certain nerve cells. BDNF and NGF are both neurotrophins. Neurotrophins are proteins that help nerve cells develop, function and respond to changes in the environment.
A study from 2007, scientists measured neurotrophin gene expression in several regions of the brain. Gene expression is the process by which information stored in a gene is used to produce a functional molecule, such as RNA or a protein.
The results differed across the brain region studied. BDNF and NGF expression increased the hippocampus, while BDNF expression also increased in the brainstem and cerebellum. NGF expression decreased in the frontal cortex.
This is important because it shows that the changes were specific to the gene and brain region being measured.
A 2006 study looked at how Semax affected BDNF in the hippocampus part of the brain involved in learning and memory. The results showed changes in BDNF and the way it sends signals within brain cells.
Both studies help explain why BDNF and NGF appear frequently in Semax research.
Other studies have examined Semax under conditions of cerebral ischaemia, reduced blood flow to the brain. These studies look at how Semax may affect molecular responses associated with neurological stress and changes in brain tissue.
In this 2010 study, scientists investigated genes connected with neurotrophins after cerebral ischaemia. They tracked transcription, the process of copying information from DNA to RNA, so that it can be used by a cell.
Changes were recorded in genes connected with BDNF, NGF and other neurotropic pathways. These changes appeared at different times during the experiment, showing that the response involved several genes rather than one single pathway.
A separate 2020 study, looked more broadly at gene activity in brain tissue under experimental ischaemic conditions. It found changes in genes associated with inflammatory processes and neurotransmission, the way nerve cells communicate using chemical or electrical signals.
These studies have helped researchers explore the molecular response to neurological stress.
Human research is limited, but one area that has been explored is functional connectivity, the statistical relationship between activity in different regions of the brain.
In this 2018 study, scientists used functional magnetic resonance imaging (fMRI), a scanning method that detects changes associated with brain activity.
Their analysis focused on the default mode network, a group of connected brain regions that is usually active while a person is resting and not concentrating on an eternal task.
Differences in connectivity were observed following Semax administration.
The study measured brain network activity rather than memory, attention or cognitive performance. Its findings should therefore be understood as imaging observations, not evidence of a clinical benefit.
Overall, Semax research is not limited to one proposed mechanism. It covers neurotrophic signalling, gene activity during neurological stress and patterns of communication within the brain.
Selank research mainly looks at pathways involving GABA, gene activity connected with neurotransmission and communication between nervous and immune systems. As with Semax, much of the available evidence comes from laboratory and animal studies.
Selank is often described as a calming compound because of its connection with GABA. However, the research suggests that this relationship is more complex than Selank simply activating a GABA receptor.
In this 2016 study, scientists looked at genes involved in neurotransmission in the frontal cortex. They found changes in several genes after Selank was given. Some of these changes were similar to those observed with GABA, suggesting that Selank may interact with processes connected to GABA signalling.
A 2017 laboratory study produced a different result. Selank alone did not directly change the activity of the GABA related genes included in the experiment. However, it altered some of the changes observed when GABA was present.
This suggests that Selank may influence how cells respond to GABA rather than acting as GABA itself. The findings also show why Selank cannot be described through one simple receptor mechanism.
Both studies were conducted using animals or cultured cells, so they do not establish how the same processes work in humans.
Selank has also been studied in connection with BDNF, which was discussed earlier in relation to Semax.
A 2008 study examined BDNF expression in the hippocampus following Selank administration. The researchers reported changes in BDNF expression, adding another possible pathway to Selank research.
This overlap does not mean that Selank and Semax affect BDNF in the same way. The studies used different conditions, measurement times and research models. Each finding must therefore be interpreted within the experiment in which it was observed.
Selank was developed from tuftsin, a peptide associated with immune regulation. This has led researchers to explore whether Selank interacts with signals shared by the nervous and immune systems.
A 2008 study examined immune markers in laboratory samples and in a group of people with anxiety related conditions. The research included measurements of interleukin 6 (IL 6), a cytokine used by immune cells to communicate.
Changes were reported in IL 6 and other cytokine measures. However, the study was small, and only limited information about its methods is available in English. Its findings should therefore be treated as early evidence that requires further independent research.
Selank research covers more than GABA alone. It also includes BDNF and communication between the nervous and immune systems, although the evidence remains limited and comes from several different types of study.
Molecular origin | Main research pathways | |
Semax | Derived from a fragment of ACTH | Places greater emphasis on neurotrophic signalling, gene activity during neurological stress and communication between different brain regions |
Selank | Developed from tuftsin | Focused more on pathways involving GABA, genes connected with neurotransmission and communication between the nervous and immune systems. |
There is some overlap between these areas. Both compounds have been studied in connection with BDNF and gene expression. However, this does not mean that they act through the same pathways or produce the same biological responses.
Understanding how related compounds can lead to different research questions can be difficult.
Our specialists offer 1:1 consultations to help you interpret the available peptide research and understand which areas may be relevant to your interests.
Schedule your 1:1 consultation today!
Semax and Selank are both synthetic heptapeptides, meaning that they contain seven amino acids. They also share the same final Pro Gly Pro sequence. However, their complete structures and molecular origins are different. Semax is derived from ACTH, while Selank was developed from tuftsin.
The compounds emerged from the same wider area of Russian peptide research and have both been investigated in relation to the central nervous system. Their similar length and shared final sequence have also encouraged comparisons. However, they have been studied through different biological pathways and research models.
The available human studies examine different questions and cannot be used to make a simple strength comparison. Semax has been included in human imaging research, while Selank has appeared in small studies involving neurological and immune measures. Both evidence bases remain limited and require further independent research.
They can be included in the same research programme, but controlled evidence involving combined exposure is limited. A suitable study would need separate Semax, Selank, combined and comparison groups. This would allow researchers to determine which compound was connected with any changes observed.
Written by Elizabeth Tito, BSc Genetics, MPH
Elizabeth is a science and medical writer specialising in peptide science, longevity medicine, mitochondrial health, metabolic optimisation and regenerative health research. With a BSc in Genetics and a Master’s in Public Health, she combines a strong scientific foundation with experience translating complex biomedical research into clear, clinically informed education for the Peptide Therapy and longevity medicine space. Her work is centred on interpreting emerging peptide, metabolic and longevity research with scientific accuracy, clinical awareness and a clear understanding of how these therapies are being discussed and applied in modern health optimisation.
